DDInter1485 DDInter1676
Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (mc-vc-PAB) that covalently attaches MMAE to polatuzumab. Polatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 and was approved by Health Canada on July 9, 2020.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Polatuzumab vedotin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enzalutamide
Polatuzumab vedotin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Simvastatin
Polatuzumab vedotin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Secnidazole
Polatuzumab vedotin {u} may lead to a major life threatening interaction when taken with {v} Clarithromycin
Polatuzumab vedotin {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Polatuzumab vedotin may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Polatuzumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin
Polatuzumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Polatuzumab vedotin may lead to a major life threatening interaction when taken with Clarithromycin
Polatuzumab vedotin may lead to a major life threatening interaction when taken with Upadacitinib